自沪深证券交易所成立以来，中国股票市场的发展至今已有二十多年的历史，在这二十多年的发展历程中，中国股票市场的规模不断壮大与规范，股票市场信息披露不断完善，监管体制不断健全，机构投资者队伍不断壮大。随着我国成功进入WTO和引入QFII（合格境外投资机构），使得中国股票市场正在加快与国际接轨的步伐，上市公司的基本面开始成为股票定价的重要因素，价值投资逐渐成为主要的投资理念。而财务数据是反应公司价值最直接有效的指标。生物制品行业其股价的稳定性、抗跌性近年来越来越受众多投资者的关注，本文通过借助财务数据对生物制品行业公司内在价值影响股价的分析，使投资者在生物制品行业找到正确的受益投资对象。%Since Shanghai and Shenzhen stock exchange was founded, the Chinese stock market development has been twenty years of history. In the twenty years of development history, the scale of Chinese stock market is growing and being normal, the stock market information disclosure and the regulatory system constantly improved, and institutional investors are steadily on the increase. With China's successful entry into WTO and introduction of QFII (qualified foreign investment institutions), Chinese stock market is to speed up the pace with international standards, and the listed company fundamentals has become an important factor of the stock price, the value investment gradually become the main investment philosophy. And financial data is the most direct and efficient index reflecting company value. Biological products industry is getting more and more attention of many investors with its share price stability and resistance to drop in recent years. With the help of financial data for biological products industry company intrinsic value influence share price analysis, this paper helps investors in biological product industry to find the right benefit investment object.
展开▼
机译：中国双重上市公司a、h股价差影响因素的实证研究 =An Empirical Study on the Influence Factors of Price Difference between A-share and H-share of China's Dual-listed Companies
